| 前收市價 | 120.20 |
| 開市 | 120.20 |
| 買盤 | 0.00 x 無 |
| 賣出價 | 0.00 x 無 |
| 今日波幅 | 120.20 - 120.20 |
| 52 週波幅 | 92.80 - 121.20 |
| 成交量 | |
| 平均成交量 | 0 |
| 市值 | 304.444B |
| Beta 值 (5 年，每月) | 0.40 |
| 市盈率 (最近 12 個月) | 143.10 |
| 每股盈利 (最近 12 個月) | 0.84 |
| 業績公佈日 | 2024年7月30日 |
| 遠期股息及收益率 | 2.87 (2.39%) |
| 除息日 | 2024年6月17日 |
| 1 年預測目標價 | 無 |
- Yahoo Finance Video
The 30-stock secret: ‘Don’t fight Papa Dow’
JC Parets, founder and chief strategist at All Star Charts, explains why fighting the Dow Breadth is futile and how embracing the approach can simplify your market analysis significantly. He spoke with Yahoo Finance’s Jared Blikre and Sydnee Fried on "Stocks in Translation." Listen to the full episode here, or wherever you get your podcasts. This post was written by Jared Blikre
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
ZacksMerck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
